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To the Editor,
It is well-known that β-thalassemia is associated with changes 
in plasma lipids and lipoproteins [1,2,3]. To our knowledge, no 
data are available on lipid profiles in Turkish β-thalassemia 
major (TM) and β-thalassemia trait (TT) patients together. The 
aim of this study was to evaluate lipid profiles in two groups of 
patients with β-TM and β-TT and to compare them with healthy 
controls. The study included a total of 311 subjects. Group 1 
included 131 β-TM patients (mean age: 16.3±7.58 years). Group 
2 included 68 β-TT patients (mean age: 7.25±4.43 years). Group 
3 consisted of 112 age- and sex-matched healthy controls (mean 
age: 9±4.7 years). Serum ferritin level was 2487±1103 (range: 
661-5745) ng/mL in Group 1. In comparing the correlation 
between ferritin and lipid parameters, while a significantly 
negative relationship was detected between ferritin and high-
density lipoprotein cholesterol (HDL-C) (p=0.000, r=-0.602), a 
significantly positive relationship was detected between ferritin 
and triglyceride (TG) levels (p=0.02) in TM patients. Serum lipid 
profiles of the 3 groups are shown in Table 1.
Previous studies have shown total serum cholesterol, HDL-C, 
lower low-density lipoprotein cholesterol (LDL-C), and higher 
TG in β-TM patients compared to healthy controls [1,2,3]. In 
our study, we found lower serum total cholesterol, lower 
HDL-C, LDL-C, and higher TG in β-TM patients compared to 
healthy controls. The pathophysiology of hypocholesterolemia 
in thalassemia remains obscure, although several mechanisms 
have been proposed; plasma dilution due to anemia, increased 
cholesterol requirement associated with erythroid hyperplasia, 
macrophage system activation with cytokine release, and 
increased cholesterol uptake by the reticuloendothelial system 
[4,5]. Previous studies reported different variations in lipid 
profiles of β-TT patients [6,7]. In our study, we demonstrated 
Serum Lipids in Turkish Patients with β-Thalassemia Major and 
β-Thalassemia Minor
Türk β-Talasemi Majör ve β-Talasemi Minör Hastalarının Serum Lipidleri
Yasemin Işık Balcı1, Şule Ünal2, Fatma Gümrük3
1Pamukkale University Faculty of Medicine, Department of Pediatric Hematology, Denizli, Turkey
2Hacettepe University Faculty of Medicine, Department of Pediatric Hematology, Ankara, Turkey
3Hacettepe University Faculty of Medicine, Department of Radiology, Ankara, Turkey
73
Turk J Hematol 2016;33:71-83
similar lipid profiles in β-TT patients and healthy controls. Based 
on statistical insignificance, we considered that the effects 
of lipid profile on the development of atherosclerotic vessel 
disease were similar in both β-TT patients and the healthy 
control group. Serum iron and iron stores, expressed as elevated 
ferritin levels, have been implicated in coronary artery disease. 
Iron overload depletes the antioxidant and HDL-C levels. Lower 
HDL-C level is an important risk factor for development of 
coronary heart diseases [8]. We found significant relationships 
of serum ferritin levels with TG and HDL-C in β-TM patients. 
These results indicate that β-TM patients who need life-long 
red blood cell transfusions should receive chelation therapy not 
only for iron overload-induced congestive heart failure but also 
in order to prevent cardiovascular diseases resulting from lipid 
profile alterations. 
In conclusion, lipid profiles of β-TM patients differed from 
those of β-TT patients and healthy controls. The present study 
demonstrates that lower levels of HDL-C in β-TM should be a 
reason for concern for better evaluation of the cardiovascular 
risk factors in β-TM. In order to reduce the effects of lipid 
metabolism on cardiovascular disorders, an effective chelating 
therapy is essential in TM patients.
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Table 1. Lipid profiles and their significance in patients with β-thalassemia major, patients with β-thalassemia trait, and 
controls.
Group 1 Group 2 Group 3 p-values
β-TM (n=131) β-TT (n=68) Control (n=112) Groups 1-2 Groups 1-3 Groups 2-3
T-Chol 118.5±30.6 145.6±27.6 154.3±31.7 0.00 0.00 NS
LDL-C 59.1±27.6 82.5±24.9  89.6±26.1 0.00 0.00 NS
HDL-C 34.4±11.2 45.7±12.2 45.5±11.1 0.00 0.00 NS
TG 121.8±50.8 82.9±34.6  97.8±52.4 0.00 0.00 NS
T-Chol: Total cholesterol, LDL-C: low-density lipoprotein cholesterol, HDL-C: high-density lipoprotein cholesterol, TG: triglyceride, β-TM: β-thalassemia major, β-TT: β-thalassemia 
trait, NS: non-significant. 
